Reuters logo
Lundbeck gets U.S. approval for epilepsy drug for children
October 28, 2013 / 3:12 PM / 4 years ago

Lundbeck gets U.S. approval for epilepsy drug for children

COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck has won approval in the United States of its epilepsy drug, Sabril, to be used in children aged 10 years and older.

Lundbeck said in a statement on Monday the United States Food and Drug Administration (FDA) had approved Sabril as an add-on therapy for the treatment of refractory complex partial seizures in children who have inadequately responded to several other treatments.

Reporting by Mette Fraende; editing by David Evans

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below